The central goal of NIH’s 3^rd AD Summit is tocontinue the development of an integrated multidisciplinary research agendanecessary to address critical knowledge gaps and accelerate the discovery anddelivery of efficacious treatments for AD patients at all stages of disease.More than 500 leading researchers, innovators and public advocates fromacademia, industry, the not-for-profit organizations and the federal governmentare expected to attend.